IGF::OT::IGF

Biospyder Technologies, Inc., Carlsbad CA

Investigators

Abstract

NCATS has as an objective the affordable high throughput screening (HTS) of compounds to assess safety and mechanistic pathways perturbed by those compounds. This requires a broad assay covering the 1000 to 2000 pathways known today. RASL-Seq has the potential to provide a low cost assay of 1000 or more genes that can be performed in high throughput, as required of a screening assay, and permit pathways that are modulated and safety mechanisms that are perturbed to be identified . The requirements are to: i) implement commercial 384-well kits and a high throughput assay protocol for a RASL-Seq high throughput screen (HTS) measuring the Tox21 NCATS Hu l 400 set of genes; ii) implement the gene content of the Tox21 NCATS Hu l 400; iii) implement a mouse and a rat version of the Tox21 NCATS Hu l 400; iv) evaluate and validate improvements to the assay reagents and protocol and then implement these in the kits; v) evaluate protocol and hardware for, and if feasible and if doing so will reduce the cost/sample by at least 5-fold, implement kits for assay processing in 1536-well format; vi) automate the data analysis process; and vii) l ink the gene content to pathway databases to facilitate the interpretation of results.